Pfizer Stock News

Two doses of the Pfizer Inc (PFE.N) and BioNTech SE (22UAy.DE) COVID-19 vaccine was protective against severe disease in children aged 5 to 11 during the recent Omicron variant surge, but quickly lost most of its ability to prevent infection in the age group, according to a study by New York State researchers. The vaccine’s […] The post Pfizer COVID Vaccine Effective Among Children — Study appeared first on Uzalendo News .

ET Intelligence Group: The Street frowned upon Indian drug major Biocon''s move to buy the biologic business of its US business partner Viatris through its subsidiary Biocon Biologics (BBL). The Biocon stock lost 11.2% on Monday as analysts were concerned about high deal valuations, an increase in Biocon''s debt burden and execution risks in a still-emerging and complex area of biosimilars.The $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of Biocon. With this deal, BBL is buying out the biosimilar portfolio of its long-time collaborator Mylan that merged with Pfizer''s Upjohn business to become Viatris. The acquisition will allow BBL to acquire regulatory, supply chain and commercialisation capabilities in the developed markets. It also gets rights to key in-licensed therapies including biosimilar Adalimumab (used to treat autoimmune conditions) and an option to acquire the Viatris''s rights for biosimilar Aflibercept (used to treat macular disorders) at a cost of $175 million. 89914048BBL has a portfolio of 20 biosimilars - out of which seven have been commercialised.For the December quarter, it earned revenues of ₹981 crore, 28% higher than a year ago, with a core operating profit (Ebitda) margin of 38%.

New data from New York state shows the effectiveness of Pfizer’s Covid vaccine for kids ages 5 to 11 dropped from 68 percent in mid-December to 12 percent by the end of January as the omicron variant spread. The findings have not been peer-reviewed. Pfizer says itandapos;s now evaluating …

New research out of New York found the protection of vaccine against infection in kids aged 5 to 11 dropped from 68% to 12%.

A new study of 1.2 million children found the shot still prevents severe illness in them but offers virtually no protection against infection.

Welcome to Monday''s Overnight Health Care, where we’re following the latest moves on policy and news affecting your health. Subscribe here: thehill.com/newsletter-signup Since the season finale of Euphoria was last night, send us your hot takes…

New York state health officials found that the two-dose jab offers minimal protection against infection for kids aged 5 to 11 about a month after full vaccination.

Pfizer’s COVID-19 vaccine was not effective in preventing infection among children aged 5 to 11, according to a new study. Researchers in New York also found indications that the vaccine effectiveness against severe disease plummeted. The researchers, with the New York State Department of Health and the University at Albany School of Public Health, examined […]

Data revealed Monday by the New York State health department shows that the Pfizer COVID-19 vaccine is not very effective at preventing infection in children aged five to 11 years old.

The effectiveness of the Pfizer/BioNTech Covid-19 vaccines for children waned quickly during the Omicron surge, especially among children ages 5 to 11, but was still protective against severe disease, according to new data from the New York State Department of Health.

Strikingly higher rates of decline in effectiveness for younger children suggest the lower dose they receive may be the reason The Pfizer/BioNTech Covid-19 vaccine is less effective in children aged five to 11 than in adolescents and adults, according to new data from New York state health officials. The new research was announced shortly after federal authorities relaxed masking guidance and a day after Eric Adams, the mayor of New York, said he would probably follow Governor Kathy Hochul in ending a mask mandate in city schools. Continue reading…

A newly published study conducted in New York indicated that the protection from Pfizer (PFE)/BioNTech (BNTX) COVID-19 vaccine wanes more rapidly in children aged 5 – 11 than in those…

The Pfizer coronavirus vaccine is significantly less effective in children aged 5-11 than it is in older kids, a new study finds, raising questions about the correct dose to give to the young. The study from researchers at the New York State…

“We continue to study and assess real-world data from the vaccine." The post Pfizer shot is far less effective in ages 5-11 than in older kids appeared first on Boston.com .

‘In the Omicron era, the effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11 years,’ a new study says